Yes, for most people. 92% of 228 people who reported on Retatrutide for weight loss say it improved. 5% noticed no change and 4% say it got worse. That is about the typical result for weight loss (91% across 22 options).
High-risk compound. Not an approved supplement; serious risks and legal restrictions apply. Nothing here is a recommendation to use it.
Ranked #5 of 22 for weight loss.
“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
“I’ve tried Reta and it melted fat away at 1mg - I really disliked the increased heart rate (and it was only 8bpm) and the nuking of my HRV.”
“I lost 115 lbs in the last year (260 → 145)...retatrutide seemed to finally address my insulin resistance.”
“I've already lost around 10-15 lbs... My energy is dramatically better and more consistent.”
Conclusion: This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Conclusion: GLP-1 RAs and co-agonists are efficacious for weight loss, with reported safety concerns predominantly gastrointestinal in nature, when used among adults with overweight or obesity and without diabetes.
Conclusion: Retatrutide (both doses) and tirzepatide exhibited superior efficacy compared to other GLP-1 receptor agonists and polyagonists in reducing body weight and waist circumference. Patients without T2DM, those with a high BMI, and individuals undergoing longer treatment cycles demonstrated significantly greater weight loss and reductions in waist circumference. Dual or triple receptor agonists (GLP-1 plus glucose-dependent insulinotropic polypeptide and/or Glucagon receptor) are more effective for weight loss than GLP-1 receptor agonists.
Information only — not medical advice. How we count